CrushSCI.com
42.4Average days
41Median days
12Fastest days
99Longest days
3,4682025 publications

Paper Review Records

All Paper Review Records

15 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.

44 days

In Search of Long-Term Disease Control: CAR T-Cell Therapy With Axicabtagene Ciloleucel or Allogeneic Hematopoietic Cell Transplantation Against Relapsed/Refractory Large B-Cell Lymphoma

Authors
Markus Maulhardt; Lina J. Kolloch; Gina Westhofen; Enver Aydilek; Margarete E. Laage; Christian Plate; Judith Büntzel; Alexander C. Angleitner; Kristian Thomson; Wolfram Jung; Justin Hasenkamp; Evgenii Shumilov; Gerald G. WulfShow moreShow less
Affiliations
Department of Hematology and Medical Oncology, University Medical Center Goettingen, Goettingen, Germany; Department of Hematology and Oncology, University Hospital Muenster, Muenster, Germany; Evangelisches Klinikum Bethel, University Hospital Bielefeld, Bielefeld, Germany; Department of Hematology, Oncology and Palliative Care, Klinikum Magdeburg, Magdeburg, GermanyShow moreShow less
Source PDF DOI Publisher page
31 days

Real-World Delivery, Dose Adaptation, and Molecular Monitoring of Gilteritinib, Venetoclax, and Azacitidine in Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia

Authors
Meiling Chen; Yuanzhong Chen; Shaoyuan Wang; Feng’e Yang; Jing Zheng; Danhui Fu; Jia Lin; Xiaofan Li; Nainong LiShow moreShow less
Affiliations
Department of Hematology, Fujian Institute of Hematology, Fujian Provincial Key Laboratory on Hematology, Fujian Medical University Union Hospital, Fuzhou, Fujian, China; Translational Medicine Center on Hematology, Fujian Medical University, Fuzhou, Fujian, China; Hematopoietic Stem Cell Transplantation Center, Fujian Institute of Hematology, Fujian Provincial Key Laboratory on Hematology, Department of Hematology, Fujian Medical University Union Hospital, Fuzhou, Fujian, ChinaShow moreShow less
Source PDF DOI Publisher page
41 days

Sequential TKI Treatment in Patients With Chronic Phase Chronic Myeloid Leukemia Resistant to Frontline Nilotinib or Dasatinib Therapy. A Real-Life Survey From the Italian Campus CML Network

Authors
Gabriele Gugliotta; Mario Annunziata; Isabella Capodanno; Davide Rapezzi; Immacolata Attolico; Marianna Caramella; Iolanda D. Vincelli; Antonella R. Rossi; Mario Tiribelli; Alessandra Malato; Michele Cimminiello; Vincenzo Accurso; Massimiliano Bonifacio; Sara Galimberti; Giuseppina Loglisci; Elisabetta Abruzzese; Monica Bocchia; Antonella Gozzini; Micaela Bergamaschi; Maria C. Miggiano; Agostino Tafuri; Grazia Sanpaolo; Anna R. Scortechini; Monica Crugnola; Debora Luzi; Luigiana Luciano; Gianni Binotto; Roberto Latagliata; Fausto Castagnetti; Alessandro Allegra; Giorgina Specchia; Uros Markovic; Gianantonio Rosti; Robin Foà; Giuseppe Saglio; Massimo Breccia; Fabio StagnoShow moreShow less
Affiliations
Institute of Hematology “Seràgnoli”, IRCCS Azienda Ospedaliero Universitaria di Bologna, Bologna, Italy; Hematology Unit, Cardarelli Hospital, Naples, Italy; Hematology Unit, Azienda Unità Sanitaria Locale - IRCCS, Reggio Emilia, Italy; S.C. Ematologia, Cuneo, Italy; Hematology and Stem cell Transplantation Unit, Bari, Italy; SC Hematology, Niguarda “Ca Granda” Hospital, Milan, Italy; Dipartimento Emato-Oncologia A.O.“Bianchi-Melacrino-Morelli”, Reggio Calabria, Italy; Division of Hematology and BMT, Department of Medical Area, University of Udine, Udine, Italy; UOC Oncoematologia, Palermo, Italy; Hematology and Bone Marrow Transplantation Unit, San Carlo Hospital, Potenza, Italy; UO di Ematologia, Divisione di Oncologia, AOU Policlinico “Giaccone” Università degli Studi di Palermo, Palermo, Italy; Department of Engineering for Innovation Medicine, Section of Innovation Biomedicine, Hematology Area, University of Verona, Verona, Italy; Department of Clinical and Experimental Medicine, Section of Hematology, University of Pisa, Pisa, Italy; Hematology Unit, “Vito Fazzi” Hospital, Lecce, Italy; Hematology Department, “S. Eugenio” Hospital, Tor Vergata University, Rome, Italy; Hematology Unit, University of Siena, Siena, Italy; Hematology Unit, AOU Careggi, University of Florence, Florence, Italy; IRCCS Ospedale Policlinico S. Martino, Dipartimento di Oncologia ed Ematologia, Dipartimento di Oncologia, S.S.D Malattie del Sangue e Neoplasie Degli Organi Emolinfopoietici, Genova, Italy; Hematology Department, San Bortolo Hospital, Vicenza, Italy; Hematology Unit, University Hospital Sant'Andrea-Sapienza, Rome, Italy; Division of Hematology, Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy; Hematology Unit, Azienda Ospedaliero Universitaria Ospedali Riuniti, Ancona, Italy; Hematology Unit, University Hospital of Parma, Parma, Italy; Onco-Hematology Department, AO Santa Maria, Terni, Italy; Division of Hematology and Bone Marrow Transplantation, University of Naples Federico II, Naples, Italy; Department of Medicine, Hematology and Clinical Immunology, Padua School of Medicine, Padua, Italy; Hematology Unit, Viterbo, Italy; Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy; Hematology Section, AOU Policlinico “G. Martino”, University of Messina, Messina, Italy; Division of Hematology, A.O.U. “Policlinico-San Marco”, University of Catania, Catania, Italy; IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy; Hematology, Department of Translational and Precision medicine, Sapienza University of Rome, Rome, Italy; Divisione Universitaria di Ematologia e Terapie Cellulari, Torino, ItalyShow moreShow less
Source PDF DOI Publisher page
84 days

Immunoglobulin D-Associated AL Amyloidosis: Clinical Features and Outcomes

Authors
Sarika D. Gurnani; Andrew Staron; Lisa M. Mendelson; Natasha J. Burke; Vaishali SanchorawalaShow moreShow less
Affiliations
Amyloidosis Center, Boston University Chobanian & Avedisian School of Medicine and Boston Medical Center, Boston, MAShow moreShow less
Source PDF DOI Publisher page
71 days

Safe Integration of Radiation Therapy With Bispecific Antibodies in Relapsed/Refractory B-cell Lymphomas

Authors
Jonathan A. Baron; Monica Chelius; Gurbani Singh; Michael D. Schad; Melanie Berger; Emeline R. Chong; Colin J. Thomas; Jordan S. Carter; Michael R. Cook; Sunita D. Nasta; Daniel J. Landsburg; Stefan K. Barta; Jakub Svoboda; Stephen J. Schuster; Nikhil Yegya-Raman; Michael J. LaRiviere; John P. Plastaras; Elise A. Chong; Harper HubbelingShow moreShow less
Affiliations
Department of Radiation Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA; Division of Hematology and Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA; Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PAShow moreShow less
Source PDF DOI Publisher page
23 days

Clonal Hematopoiesis in Newly Diagnosed Multiple Myeloma: Associations With Neutropenia, Supportive Care Burden, and Survival

Authors
Ahmet Yigitbasi; Fulya Oz Puyan; Hakki Onur Kirkizlar; Tugcan Alp Kirkizlar; Nuray Can; Ebru Tastekin; Seyma Keles Karahan; Elif Gulsum Umit; Ahmet Muzaffer DemirShow moreShow less
Affiliations
Department of Hematology, Faculty of Medicine, Trakya University, Edirne, Türkiye; Department of Pathology, Faculty of Medicine, Trakya University, Edirne, Türkiye; Department of Internal Medicine, Faculty of Medicine, Trakya University, Edirne, TürkiyeShow moreShow less
Source PDF DOI Publisher page

FAQ

How long does Clinical Lymphoma Myeloma & Leukemia take to review a manuscript?

As of 2026-11-14, CrushSCI has 15 complete review records for Clinical Lymphoma Myeloma & Leukemia. The fastest paper went from submission to acceptance in 12 days (Knowledge, Awareness, and Practice Patterns of Nephrologists in the Diagnosis and Management of Multiple Myeloma (MIND-MM Study): A Cross-Sectional, Web-Based, CHERRIES-Compliant Survey with Position Statement from the Indian Myeloma Academic Groupe (IMAGe) and Indian Society of Nephrology (ISN), received 2026-05-31, accepted 2026-06-12); the slowest took 99 days. The average is 42.4 days and the median is 41 days.

Expert Matching · Case Demo

Turn Your Submission Goalsinto a Verifiable Journal Plan

Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.

We will reply within 30 minutes.

CrushSCI online

Client

I work in environmental engineering and need an SCI paper published within three months. I have no grant funding or prominent co-author. Which journals could I target?

CrushSCI

Yes. We will first screen for feasibility against the 90-day deadline, then identify comparable papers without grant support or prominent co-authors. The final shortlist will prioritize research quality and journal scope.

Suggested title
Machine Learning and Life-Cycle Assessment for Predicting and Optimizing Carbon Emissions in Urban Wastewater Treatment

SampleLatest 5 valid paper samples from 2026

Average review59.6 days

Median65 days

Contact CrushSCI

Contact CrushSCI

Leave your email address to discuss academic polishing, structural refinement, or one-to-one guidance.

We will reply within 30 minutes.

Selected service: Academic Consulting Service

Leave your email address

Or email us directly at leader@crushsci.com

Enter your email address so we can reply. Your details will remain private.